First Manhattan Wants to Place Vivus CEO Wilson

barbara.lempert NEW YORK, July 2, 2013  (AP) — Vivus Inc.’s biggest shareholder said Tuesday that it plans to replace the company’s CEO if it is successful in ...

First patients screened for Phase 2B studies with GLPG0634

barbara.lempert •    First rheumatoid arthritis patients screened in Belgium •    Galapagos on track with DARWIN Phase 2B program in rheumatoid arthritis •    875 ...

Hospira’s Inflectra the first biosimilar monoclonal antibody to receive positive opinion from EMA’s CHMP for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis

barbara.lempert Hospira’s Inflectra™ (infliximab) the first biosimilar monoclonal antibody to receive positive opinion from EMA’s CHMP for rheumatoid arthritis, inflammatory ...

Regeneron Announces First Recipients of Annual Regeneron Prize for Creative Innovation

barbara.lempert New National Prize Recognizes Talented Early-Career Scientists Poised to Make Important Contributions to Scientific Discovery TARRYTOWN, N.Y., June 27, 2013 /PRNewswire/ ...

Facing A Tight Deadline, Long-Term Care Panel Holds First Meeting

barbara.lempert By Susan Jaffe KHN News Jun 28, 2013 The Commission on Long-Term Care held its first meeting Thursday on Capitol Hill with some members acknowledging that their ...

FDA approves Brisdelle, first nonhormonal treatment for hot flashes

Eric Palmer The FDA has approved the first nonhormonal treatment for hot flashes, which affect up to 75% of women and can drag on for 5 years or more. FiercePharma News

First Manhattan recruiting new CEO for Vivus ahead of proxy vote

Carly Helfand First Manhattan Company, Vivus' top shareholder with nearly 10 percent, has made its aims well known. It wants a leadership shakeup–and it wants it bad. FiercePharma ...

Prollenium Medical Technologies Inc. Launch First and Only Dermal Filler Manufacturing Facility in Canada

barbara.lempert AURORA, ON, June 12, 2013 /CNW/ – Prollenium Medical Technologies Inc. has opened its new facility, just north of Toronto, making it the only manufacturer of ...

Agios selling $86M IPO to fund its first cancer drug trials

John Carroll FierceBiotech News

Medicago is First in the World to Report Positive Interim Results for its H7N9 Pre-Clinical Trial

barbara.lempert – The H7 VLP vaccine candidate induces an antibody response after a single dose in mice- QUEBEC CITY, June 6, 2013 /CNW/ – Medicago Inc. (TSX: MDG; OTCQX: ...

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of Leukemia

barbara.lempert – Partial results expected in Q4 2013 – JERUSALEM–(BUSINESS WIRE)– BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, ...

Zydus Pioneers A Breakthrough With Lipaglyn, India’s First NCE to Reach the Market

barbara.lempert MUMBAI, India, June 5, 2013 /CNW/ – Lipaglyn™ is the first Glitazar to be approved in the world and the first NCE discovered and developed indigenously by an ...
Page 5 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS